Hey, believe it! Dr Reddy's Laboratories just dropped their new diabetes hero, Obeda, ready to take on the GLP-1 market in India! With a price cut of 62% compared to Ozempic, they're aiming to sell 12 million pens this year. This is just the start, and they're determined to be in the top five! Let's go, Team Obeda!

Health

